1. The plaintiff's appeal is dismissed.

2. The plaintiff's claim extended in the trial is dismissed.

3...

1. The following facts may be found either in dispute between the parties or in full view of the purport of the entire pleadings in each entry in Gap evidence Nos. 1 to 5, Eul evidence Nos. 4 and 5:

On June 2, 2014, the Plaintiff agreed with the Defendant, the insurance company, the insured, the period of insurance, and the payment period of the Plaintiff’s insurance premium of ten years each, and the insurance premium of 38,800 won each, and entered into a non-dividend cancer insurance contract (hereinafter “instant insurance contract”). (b) The instant insurance contract’s guarantee includes “Cancer cancer” (or 40 million won only once before the first time when the cause for payment occurs prior to the date on which two years elapsed from the date of the insurance contract, and 50% payment is made). However, the terms and conditions relating thereto are as follows:

Article 3 [The definitions and diagnosis confirmation of “Apam” and “Apam”] (1) “Apam” in this Agreement refers to diseases specified in attached Table 4 [excluding Apam and Apamam, which are subject to the Korean Standard Disease Classification (excluding other Apam and Apamam)].

다만, 전암(前癌) 상태(암으로 변하기 이전 상태(premalignant condition or condition with malignant potential), 분류번호 C44(기타 피부의 악성신생물(암))과 분류번호 C73(갑상선의 악성신생물(암))에 해당하는 질병은 제외합니다. ⑥ 암, 기타피부암 및 갑상선암의 진단확정은 병리 또는 진단검사의학의 전문의사 자격증을 가진 자에 의하여 내려져야 하며, 이 진단은 조직(fixed tissue)검사, 미세바늘흡인검사(fine needle aspiration biospy) 또는 혈액검사(hemic system)에 대한 현미경 소견을 기초로 하여야 합니다. (중략) 제5조 ["경계성 종양"의 정의 및 진단확정 ① 이 계약에 있어서 “경계성 종양”이라 함은 한국표준질병사인분류 중...